Corinne Johnson
Stock Analyst at Goldman Sachs
(3.15)
# 1,409
Out of 5,182 analysts
17
Total ratings
46.67%
Success rate
20.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Neutral | $29 → $32 | $28.62 | +11.81% | 3 | Apr 15, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $28 → $34 | $21.00 | +61.90% | 3 | Apr 1, 2026 | |
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $35.38 | +10.23% | 1 | Jan 15, 2026 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $31.97 | -43.70% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $16.88 | +18.48% | 2 | Sep 16, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $30.33 | +8.80% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $128.04 | +42.14% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $66.82 | -25.17% | 3 | May 14, 2024 |
Immunovant
Apr 15, 2026
Maintains: Neutral
Price Target: $29 → $32
Current: $28.62
Upside: +11.81%
Syndax Pharmaceuticals
Apr 1, 2026
Maintains: Buy
Price Target: $28 → $34
Current: $21.00
Upside: +61.90%
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $35.38
Upside: +10.23%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $31.97
Upside: -43.70%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $16.88
Upside: +18.48%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $30.33
Upside: +8.80%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $128.04
Upside: +42.14%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $66.82
Upside: -25.17%